Clinical/Translational Cancer Immunotherapy

Section edited by F. Stephen Hodi, Jr., MD

First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies.

Previous Page Page 1 of 3 Next Page
  1. Research article

    Evaluation of dosing strategy for pembrolizumab for oncology indications

    Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pe...

    Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis and Julie A. Stone

    Journal for ImmunoTherapy of Cancer 2017 5:43

    Published on: 16 May 2017

  2. Research article

    Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

    Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogene...

    Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez and Constantin N. Baxevanis

    Journal for ImmunoTherapy of Cancer 2017 5:39

    Published on: 18 April 2017

  3. Research article

    A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood

    Exercise immunology has become a growing field in the past 20 years, with an emphasis on understanding how different forms of exercise affect immune function. Mechanistic studies are beginning to shed light on...

    Michael P. Gustafson, Ara Celi DiCostanzo, Courtney M. Wheatley, Chul-Ho Kim, Svetlana Bornschlegl, Dennis A. Gastineau, Bruce D. Johnson and Allan B. Dietz

    Journal for ImmunoTherapy of Cancer 2017 5:30

    Published on: 18 April 2017

  4. Research article

    Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death

    We have been developing a non-thermal, drug-free tumor therapy called Nano-Pulse Stimulation (NPS) that delivers ultrashort electric pulses to tumor cells which eliminates the tumor and inhibits secondary tumo...

    Richard Nuccitelli, Amanda McDaniel, Snjezana Anand, John Cha, Zachary Mallon, Jon Casey Berridge and Darrin Uecker

    Journal for ImmunoTherapy of Cancer 2017 5:32

    Published on: 18 April 2017

  5. Meeting report

    The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting

    As healthcare costs continue to rise, there has been great interest in understanding and defining the value of current therapeutic strategies for the treatment of cancer. Cancer immunotherapy has emerged as a ...

    Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton and Peter P. Yu

    Journal for ImmunoTherapy of Cancer 2017 5:38

    Published on: 18 April 2017

  6. Research article

    Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

    Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor ...

    Matthew J. Reilley, Ann Bailey, Vivek Subbiah, Filip Janku, Aung Naing, Gerald Falchook, Daniel Karp, Sarina Piha-Paul, Apostolia Tsimberidou, Siqing Fu, JoAnn Lim, Stacie Bean, Allison Bass, Sandra Montez, Luis Vence, Padmanee Sharma…

    Journal for ImmunoTherapy of Cancer 2017 5:35

    Published on: 18 April 2017

  7. Short report

    Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

    Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated remarkable efficacy in controlling the growth of multiple tumor types. Unresectable or metastatic...

    Evan J. Lipson, Mohammed T. Lilo, Aleksandra Ogurtsova, Jessica Esandrio, Haiying Xu, Patricia Brothers, Megan Schollenberger, William H. Sharfman and Janis M. Taube

    Journal for ImmunoTherapy of Cancer 2017 5:23

    Published on: 21 March 2017

  8. Research article

    Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy

    Insufficient persistence and effector function of chimeric antigen receptor (CAR)-redirected T cells have been challenging issues for adoptive T cell therapy. Generating potent CAR T cells is of increasing imp...

    Ryan Urak, Miriam Walter, Laura Lim, ChingLam W. Wong, Lihua E. Budde, Sandra Thomas, Stephen J. Forman and Xiuli Wang

    Journal for ImmunoTherapy of Cancer 2017 5:26

    Published on: 21 March 2017

  9. Research article

    Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

    T cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined. Here we report results ...

    Kristen M. Hege, Emily K. Bergsland, George A. Fisher, John J. Nemunaitis, Robert S. Warren, James G. McArthur, Andy A. Lin, Jeffrey Schlom, Carl H. June and Stephen A. Sherwin

    Journal for ImmunoTherapy of Cancer 2017 5:22

    Published on: 21 March 2017

  10. Research article

    CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo

    Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise and destroy tumour cells. Efficient engraftment of T cells and persistence in the circulation correlate wit...

    Gray Kueberuwa, Hannah Gornall, Erik Marcelo Alcantar-Orozco, Deborah Bouvier, Zainul Abedin Kapacee, Robert Edward Hawkins and David Edward Gilham

    Journal for ImmunoTherapy of Cancer 2017 5:14

    Published on: 21 February 2017

  11. Case report

    Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma

    Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent metastases a...

    Kathryn E. Beckermann, Pradeep C. Jolly, Ju Y. Kim, Jennifer Bordeaux, Igor Puzanov, W. Kimryn Rathmell and Douglas B. Johnson

    Journal for ImmunoTherapy of Cancer 2017 5:1

    Published on: 17 January 2017

  12. Research article

    Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen

    We previously demonstrated that tumor irradiation potentiates cancer vaccines using genetic modification of tumor cells in murine tumor models. To investigate whether tumor irradiation augments the immune resp...

    Gilda G. Hillman, Lyndsey A. Reich, Shoshana E. Rothstein, Lisa M. Abernathy, Matthew D. Fountain, Kali Hankerd, Christopher K. Yunker, Joseph T. Rakowski, Eric Quemeneur and Philippe Slos

    Journal for ImmunoTherapy of Cancer 2017 5:4

    Published on: 17 January 2017

  13. Research article

    A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

    Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted a...

    Andrew S. Brohl, Nikhil I. Khushalani, Zeynep Eroglu, Joseph Markowitz, Ram Thapa, Y. Ann Chen, Ragini Kudchadkar and Jeffrey S. Weber

    Journal for ImmunoTherapy of Cancer 2016 4:85

    Published on: 20 December 2016

  14. Research article

    Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

    Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been prev...

    Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, Anika E. Adeni, Hiroto Hatabu, Pasi A. Jänne, F. Stephen Hodi and Mark M. Awad

    Journal for ImmunoTherapy of Cancer 2016 4:84

    Published on: 20 December 2016

  15. Research article

    5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers

    Resistance to chemotherapy is a major obstacle in the effective treatment of cancer patients. B7-homolog 1, also known as programmed death ligand-1 (PD-L1), is an immunoregulatory protein that is overexpressed...

    Lauren Van Der Kraak, Gaurav Goel, Krishnaveni Ramanan, Christof Kaltenmeier, Lin Zhang, Daniel P. Normolle, Gordon J. Freeman, Daolin Tang, Katie S. Nason, Jon M. Davison, James D. Luketich, Rajeev Dhupar and Michael T. Lotze

    Journal for ImmunoTherapy of Cancer 2016 4:65

    Published on: 18 October 2016

  16. Research article

    Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

    Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is...

    Bridgette A. Kanz, Megan H. Pollack, Romany Johnpulle, Igor Puzanov, Leora Horn, Alicia Morgans, Jeffrey A. Sosman, Suthee Rapisuwon, R. Martin Conry, Zeynep Eroglu and Douglas B. Johnson

    Journal for ImmunoTherapy of Cancer 2016 4:60

    Published on: 18 October 2016

  17. Short report

    High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome

    VEGF-targeted therapy has become the mainstay of treatment for majority of mRCC patients. For most patients, benefit is short-lived and therefore treatment remains palliative in intent. HD IL2 is an effective ...

    S. Chow, V. Galvis, M. Pillai, R. Leach, E. Keene, A. Spencer-Shaw, A. Shablak, J. Shanks, T. Liptrot, F. Thistlethwaite and R. E. Hawkins

    Journal for ImmunoTherapy of Cancer 2016 4:67

    Published on: 18 October 2016

  18. Meeting report

    Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015

    Harnessing the immune system and preventing immune escape, the immunotherapy of cancer provides great potential for clinical application, in broad patient populations, achieving both conventional and unconvent...

    Paolo A. Ascierto, Maria Libera Ascierto, Silvia Formenti, Sacha Gnjatic, Hans Hammers, Vera Hirsh, Rolf Kiessling, Ignacio Melero, Rita Nanda, Graham Pawelec, Sandro Pignata, Pedro Romero, Daniel E. Speiser, Bernard A. Fox and Francesco M. Marincola

    Journal for ImmunoTherapy of Cancer 2016 4:62

    Published on: 18 October 2016

Previous Page Page 1 of 3 Next Page
JITC logo

Advertisement